Working in conjunction with Stacy Brown, PhD, Gatton College of Pharmacy, East Tennessee State University, Department of Pharmaceutical Sciences, Johnson City, Tennessee, and Paul Lewis, PharmD, BCPS-AQ ID, Johnson City Medical Center, Johnson City, Tennessee, Remonica Jackson presented a poster analyzing the comparative stability of compounded omeprazole suspension versus commercial omeprazole kit when stored in oral syringes under refrigerated conditions.
Evaluating samples from compounded omeprazole suspension and CutisPharma’s FIRST – Omeprazole Oral Suspension Compounding Kits using a validated high-performance liquid chromatography with ultraviolet detection method, Ms. Jackson concluded that both suspension forms can be stored in clear luerlock oral syringes under refrigeration for 14 days and retain potency between 90% and 110%. In addition, she found, the FIRST – Omeprazole suspension can be stored for the duration of the product’s beyond-use date of 30 days and retain potency between 90% and 110% of initial concentration. Finally, the data suggest that the API concentration in FIRST – Omeprazole suspension is more consistent from batch to batch than traditionally compounded omeprazole suspension.
CutisPharma, Inc.’s FIRST – Omeprazole Oral Suspension Compounding Kits enable pharmacists to quickly dispense compounded prescriptions containing widely used proton-pump inhibitors. Traditionally, compounded omeprazole oral suspensions can take up to several hours to prepare and have an unpleasant taste. With FIRST – Omeprazole, pharmacists need only add the liquid suspension to the powder, shake, and then within minutes dispense to the patient with improved flavoring.
« Click here to return to ASHP Conference Connect.
Published December 19, 2019